A rapid semi-quantitative screening method was devised for assessing the anticryptosporidial and cytotoxic effects of putative chemotherapeutic compounds. The method is suitable as an initial rapid screening procedure from which compounds demonstrating anticryptosporidial activity can be identified for further analysis. It has the advantages of speed, low cost and concurrent assessment of anticryptosporidial and cytotoxic effects and allows accurate determination of minimum lethal concentrations. Of the 71 compounds screened, six completely inhibited cryptosporidial growth at 1 WM (monensin, salinomycin, alborixin, lasalocid, trifluralin and nicarbazin) and a further eight showed significant anticryptosporidial activity at 1 or 20 WM (halquinol, bleomycin, suramin, mitomycin, doxycycline hydrochloride, toltrazuril, chloroquine phosphate and teniposide). Twelve compounds were found to have some degree of cytotoxicity at 1 WM and a further 12 at 20 WM. ß 1999 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved.
Introduction
Cryptosporidium parvum is a protozoan parasite found to infect a range of domestic and wild animals, as well as humans, worldwide [1, 2] . The parasite primarily invades the epithelium of the gastrointestinal tract of infected hosts causing asymptomatic infections or an acute or chronic cholera-like diarrhoeal disease, which can be life-threatening in immunocompromised and neonatal individuals [3, 4] . The serious nature of cryptosporidiosis in high-risk groups such as AIDS patients and neonates is compounded by the lack of curative treatment strategies. Further, a major limiting factor for the large-scale assessment of potential anticryptosporidial agents has been the lack of a simple in vitro screening method.
In this study we used a simple method for screening the activity of drugs against C. parvum in vitro. Our semi-quantitative screening method provides a rapid evaluation of anticryptosporidial drug activity as well as drug toxicity on the mammalian host cells in which the C. parvum is cultured. The use of ELISA as a screening tool is limited in that it detects the e¡ect of the compound on the target organism giving no data as to its e¡ect on the host cells. This then necessitates a second screening of the cultures in order to determine drug toxicity. Additionally the semi-quantitative method negates the need for animals for the supply of C. parvum-speci¢c antisera. This method also has the advantage of assessing the presence of all stages of C. parvum without the need for staining and counting individual parasitic stages [5] . This rapid method facilitates large-scale in vitro analysis which can be used to focus on those compounds which have an obvious anticryptosporidial e¡ect which can then be pursued in more detail in a quantitative assay or in vivo model.
Materials and methods

Parasite preparation
The C. parvum isolate used in this study was originally collected from a calf from Millicent, South Australia and subsequently passaged through mice in our laboratory. Methods used to amplify and purify oocysts from mice have been described by Meloni and Thompson [6] . Brie£y, 7-day-old mice were infected with 1^1.5U10 5 oocysts. On day 8 post infection the jejunum, ileum, caecum and colon were removed and homogenised in 0.02% Tween containing sputalysin (0.005 g ml 31 ) (Oxoid, Sydney, Australia). After several washes and ether extraction the oocysts were puri¢ed by centrifugation on a 0.5%/ 1.0% Ficoll gradient made up in phosphate-bu¡ered saline (PBS) and 16% sodium diatrizoate (Sigma Chemical Company, St. Louis, MO, USA). The oocysts were then stored at 4³C in PBS containing gentamicin 5 mg ml 31 , lincomycin 4 mg ml 31 and ampicillin 10 mg ml 31 . A pre-excystation treatment described by Meloni and Thompson [6] was used to treat oocysts immediately prior to infecting cells and consisted of exposing 0.1^1-ml aliquots of oocysts to 9 ml of freshly prepared ¢lter-sterilised distilled water (pH 2.5^3) containing 0.5% trypsin for 20 min at 37³C with frequent mixing. The excystation suspension was centrifuged at 3500 rpm for 5 min at room temperature and oocysts resuspended in RPMI 1640 (sRPMI, Sigma Chemical Co.) supplemented with NaHCO 3 (3.0 mg ml 31 ), bovine bile (0.2 mg ml 31 ) (Sigma), 1% foetal bovine serum (FBS), folic acid (1.0 Wg ml 31 ), para-aminobenzoic acid (4.0 Wg ml 31 ), pantothenic acid (2.0 Wg ml 31 ) and ascorbic acid (35 Wg ml 31 ) pH 7.4 [6] . The human enterocyte cell line HCT8 (ATCC; CCL244) was used as it has been shown to support a high level of endogenous growth of C. parvum [68 ] . The HCT8 cell line was maintained in 25-cm 2 tissue culture £asks in RPMI containing 1% FBS (Gibco) and 3 mg ml 31 sodium bicarbonate in 5% CO 2 at 37³C. HCT8 cells subcultured into 24-well plates were grown in RPMI containing 10% FBS. When cells had recently reached con£uent monolayers (4^5 days) they were ready for in vitro drug testing. Drug evaluation was performed in duplicate using 24-well plates containing 0.5 ml of fresh sRPMI and inoculated with 10 000^20 000 trypsintreated oocysts in 1 ml sRPMI per well. Plates containing inoculated cells were incubated at 37³C for 75 min in a candle jar, prior to the addition of 5 Wl drug dilution or control diluents. Drugs were added to wells such that the ¢nal concentration of diluent used never exceeded 0.34% of the ¢nal sRPMI. Plates were gently mixed for 2 min on a microtitre plate shaker and re-incubated in a candle jar at 37³C for 48 h. Drugs were tested at a high concentration (either 20 WM or 10 Wg ml 31 ) and a low concentration (either 1 WM or 0.5 Wg ml 31 ). Drugs which appeared to be completely inhibitory at 1 WM were tested at lower concentrations (0.001^0.5 WM).
Assessment of drug activity
After a 48-h incubation the wells were washed twice in PBS and ¢lled with 1 ml Hanks' balanced salt solution. Parasite growth was quanti¢ed using an inverted light microscope by scoring the presence or absence of one or more endogenous stages in ¢ve ¢elds, regardless of the number of parasites in each ¢eld, six times per well at U600 magni¢cation (i.e. 30 ¢elds per well, 60 ¢elds per drug tested) and ranked according to Table 1 . Test well ranks were compared with those of controls and drug e¡ects analysed by the non-parametric Mann-Whitney U-test (P = 0.01) using the StatView computer program (Abacus Concepts, Berkeley, CA, USA). The e¡ect of the compounds on the host cell monolayer was assessed and scored as shown in Table 1 . Where the drug had an e¡ect the rank was also converted to a per cent inhibition which is presented in parentheses beside the rank also shown in Table 1 . The minimum lethal concentration (MLC) was assumed to be the lowest concentration of drug which resulted in a total absence of visible cryptosporidial endogenous stages.
If the control well did not achieve the highest rank (4) the experiment was repeated using a more concentrated oocyst inoculum.
Antimicrobial agents (and suppliers)
Seventy-one drugs were tested for anticryptosporidial activity: metronidazole, carnidazole, ronidazole, chloroquine phosphate and dimetridazole (May and Baker), nocodazole (gift from E. Lacey, McMaster Laboratory, Commonwealth Scienti¢c and Industrial Research Organisation, Sydney), omeprazole (Astra), tetracycline (Lederle), sodium lasalocid, oxiconazole, toltrazuril and febantel (Bayer), ipronidazole, ornidazole, sulfadoxine, pyrimethamine and me£oquine hydrochloride (Roche), paromomycin (Parke-Davis), nalidixic acid (Stirling Winthrop), etoposide, teniposide, cisplatin, halquinol, mitomycin C and bleomycin (Bristol-Meyers Squibb), bacitracin (Upjohn), busulfan, atovaquone, buparvaquone, pyrimethamine, polymyxin B sulfate and parvoquone (Wellcome), quinine (Fawns and Macallan Pty Ltd), oxadazole, CC15982 (Glaxo), trimethoprim, erythromycin, sulfamethizole, sulfamethoxazole, levamisole and propamidine isethionate (gifts from Curtin University, Perth), suramin, chloramphenicol, podophyllotoxin, colchicine, lumicolchicine, 2-propionamido-5-benzoyl benzimidazole, neomycin, griseofulvin, colistin methanesulfonate, monensin sodium, praziquantel, doxycycline hydrochloride and vinblastine (Sigma), tri£uralin (Nufarm), alborixin (Sandoz), azithromycin dihydrate, pyrantel pamoate, tinidazole and £uconazole (P¢zer), salinomycin sodium (Hoechst), amprolium, sulfaquinoxaline, nicarbazin and arprinocid (Merck Sharpe and Dohme), castanospermine and swainsonine (Toxicology, Health Department of Western Australia), tylosin tartrate (Lilly), albendazole sulfoxide and albendazole sulfone (gifts from SmithKline Beecham).
Results
Results are summarised in Tables 1 and 2 and show the rank and per cent inhibition as described in the legend to Table 1 . At 1 WM suramin had a rank of 3 (33% inhibition) with no visible toxic effects on the cells. Mitomycin had a rank of 2 (67% inhibition) and had a slight e¡ect on the host cells. At this concentration monensin, salinomycin, alborixin, lasalocid, tri£uralin and nicarbazin had a rank of 1 (100% inhibition) with no e¡ect on the cells observed with tri£uralin and a slight e¡ect observed with the other compounds. Halquinol had a rank of 2 (67%) at 1 WM; however, it was cytotoxic at 20 WM. At 1 WM atovaquone had no e¡ect on the C. parvum yet had a slight e¡ect on the cells whereas at the same concentration vinblastine, podophyllotoxin and colchicine could not be assessed for their anticryptosporidial e¡ect because they caused up to 25% of the monolayer to detach. Me£oquine HCl and oxiconazole caused more than 25% detachment of the host cells at 20 WM yet had no visible e¡ect on C. parvum or host cells at 1 WM. Sodium lasalocid, atovaquone, parvaquone, podophyllotoxin, colchicine, lumicolchicine, nocodazole and vinblastine could not be assessed for their anticryptosporidial e¡ect at 20 WM as they caused the cell monolayer to detach. At 20 WM tri£uralin had a rank of 1 (100% inhibition) yet had a visible e¡ect on the host cells.
Quinine, erythromycin, chloroquine, teniposide and 2-propionamido-5-benzoyl benzimidazole had no anticryptosporidial e¡ect yet showed slight toxicity to the host cells at 20 WM. Teniposide had a rank of 2 (67% inhibition) at 20 WM with slight toxicity to the host cells yet had no e¡ect on either parasite or host cells at 1 WM. The lower drug concentrations used to determine the MLC showed that at 0.005 WM alborixin and monensin produced a rank of 1 for C. parvum with no toxic e¡ects on the host cells yet had a rank of 3 (33% inhibition) at 0.001 WM suggesting that the MLC for these drugs is between 0.001 and 0.005 WM. Similarly 0.05 WM lasalocid and salinomycin resulted in a rank of 1 with no visible e¡ect on the cells, again suggesting that the MLC is within the 0.01^0.05-WM range, however at 0.1 WM exposure to each of the four drugs resulted in slight toxicity to the cells. If 21^30 ¢elds were positive for Cryptosporidium it was given a rank of 4 (0% inhibition) and no^very low e¡ect was recorded. For 11^20 positive ¢elds the rank was 3 (33% inhibition) and a low e¡ect recorded. If 1^10 ¢elds were positive it was ranked 2 (67% inhibition) and a high e¡ect recorded and if there were no positive ¢elds for Cryptosporidium a rank of 1 (100% inhibition) and very high e¡ect were recorded. a Mann-Whitney U-test shows statistically signi¢cant e¡ect (*P = 0.01). Only compounds showing a statistically signi¢cant e¡ect are listed in the table, for a list of all compounds tested see Section 2. b Toxicity of drug on host cell : 3 = not tested; 0 = no visible toxic e¡ects; + = slight morphological changes/monolayer still intact; ++ = 12 5% monolayer lifted; +++ = s 25% monolayer lifted. c Only drug concentrations with toxicity values of 0 and + were used for assessing growth inhibition.
Discussion
In view of the devastating e¡ect of C. parvum on immunocompromised individuals including AIDS patients as well as neonates, the search for a curative treatment for cryptosporidiosis must be considered urgent. A rapid method for isolating potential chemotherapeutic agents is the ¢rst step in ¢nding e¡ec-tive treatments. The method described in this study will enable the identi¢cation of potential anticryptosporidial drugs that warrant further detailed examination. This method has been designed with the aim of high turnover of compounds rather than as an accurate assessment of IC 50 values, however, it remains an excellent system for assessing the MLC of putative anticryptosporidial agents. Determination of an accurate MLC is particularly important when assessing anticryptosporidial agents due to the fact that C. parvum has proved to be refractory to treatment both in vitro and in vivo. The use of MLC rather than IC 50 as a more appropriate tool for assessing anticryptosporidial compounds is exempli¢ed when reviewing in vivo drug trials which showed signi¢cant reductions in oocyst numbers excreted from treated animals yet oocyst numbers increased to those of controls when treatment ceased [9^12] .
Using this simple in vitro screening assay we identi¢ed several compounds that completely inhibited growth of C. parvum at 1 WM or lower (Tables 1  and 2 ). The compounds monensin, salinomycin, alborixin, lasalocid and tri£uralin have previously been shown to have anticryptosporidial activity, while the in vitro anticryptosporidial e¡ect of nicarbazin has not been reported. The drugs mitomycin C and halquinol, although not completely inhibiting growth at 1 WM, severely restricted growth.
The absence of any e¡ect of the nitroimidazoles on C. parvum at 20 WM reinforces the ¢ndings of Woods et al. [13] , who demonstrated a 5% inhibition at 5800 WM metronidazole and a total absence of inhibition at 4000 WM tinidazole. However, an in vivo study reported signi¢cant anticryptosporidial activity for metronidazole in immunosuppressed rats [11] . These results highlight the need for exercising caution when comparing in vitro with in vivo e¡ects. Conversely, the in vivo study by Lemeteil et al. [11] reported only a slight e¡ect from lasalocid whereas the current in vitro study placed the MLC for lasalocid at 0.05 WM. It is noteworthy that this di¡erence goes beyond the di¡erences between in vitro and in vivo e¡ects as Rehg [14] concurred with the current study reporting a high level of activity with lasalocid in vivo using immunosuppressed rats. Interestingly, the activity reported by Rehg [14] and a similar ¢nd-ing by Brasseur et al. [15] included therapeutic and prophylactic components. Similarly bleomycin had no e¡ect at 50 Wg kg 31 body weight day 31 in vivo [11] yet in the current study a decrease in C. parvum numbers of approximately 33% was observed at a concentration of 20 WM bleomycin. The polyether ionophore, alborixin, demonstrated anticryptosporidial activity both in vitro in the current study and in vivo [16] supporting the usefulness of the in vitro method. The absence of any e¡ect from azithromycin may be due to the limited exposure time in the current study. A previous in vivo examination of the e¡ects of azithromycin demonstrated a marked anticryptosporidial e¡ect over 9 days continuous exposure, however the infection returned on cessation of the treatment [12] . There was a high level of host cell toxicity demonstrated amongst the antimalarial drugs. Chloroquine produced 33% inhibition of C. parvum at 20 WM in the current study, similar to the 90% inhibition Woods et al. [13] found at 80 WM in vitro; however, both studies reported host cell toxicity at the lower concentrations tested. The aminoglycosides showed no anticryptosporidial activity at either the higher or lower concentrations. While paromomycin has been cited as a positive control for anticryptosporidial compounds it must be recalled that the 75^85% inhibition was achieved at a concentration of 3200 WM [17] . It may be interesting to note that in the current study a concentration of 500 WM failed to achieve a measurable decrease in C. parvum. However, the aim of this study was to examine many compounds at a lower therapeutic range as it was considered pointless to examine an e¡ect at higher concentrations due to the cytotoxicity of many compounds and the inability to achieve high concentrations in vivo.
The quinone analogues tested were disappointing in their absence of any e¡ect, particularly considering past studies which demonstrated slight in vivo and in vitro anticryptosporidial e¡ects of the hydrox-ynaphthoquinone, 566c80, albeit at very high concentrations [18] . This notwithstanding, the activities of this class of compounds cannot be completely dismissed, indeed, analogues of atovaquone may be worth examining both in terms of greater anticryptosporidial e¡ect and for lower cytotoxic e¡ects. Of the tubulin binding compounds tested, tri£uralin alone achieved signi¢cant inhibition yet demonstrated no toxicity to the host cells. While the anticryptosporidial e¡ects of the dinitroanilines are known it is important to include a benchmark for comparison of activity. Moreover, this result vindicates the use of this method as a reliable in vitro screening method. The absence of, or very low, activity of the other tubulin binding compounds, and their noted toxicity to the host cells, places them outside those compounds necessitating further studies. Similarly the absence of any observable anticryptosporidial e¡ect of the anthelmintics at the concentrations tested also removes these drugs from those to be further examined. The in vitro screening method used to assess compounds for anticryptosporidial activity in this study is simple to perform, inexpensive, does not require sophisticated equipment and can provide information on drug toxicity. The advantage of this assay method is a rapid turnover of putative anticryptosporidial agents at low cost of time and consumables. Further, the current in vitro drug study was performed using 24-well plates although it would be a simple task to scale the experiment up to 48-well plates allowing duplicate analysis of 10 compounds at two concentrations. The test is useful for identifying potential lead compounds and drugs that are worthy of further evaluation both in vitro and in vivo. It is the intention of the authors to perform in vivo studies using the compounds which demonstrated anticryptosporidial activity at achievable therapeutic concentrations.
It must also be noted that the semi-quantitative method used in the current study will underestimate the degree of inhibition due to the clumping of cryptosporidial stages such that a clump which is reduced to perhaps 10% of its former size will be counted as una¡ected. Nonetheless, this method can be used to statistically compare the e¡ects of compounds for inhibition, MLC and cytotoxicity.
